|
|
Multiple Myeloma Update From the
2015 American Society of Hematology (ASH) Annual Meeting
CME Information
Release date: December 8, 2015
Expiration date: December 31, 2016
Estimated time to complete activity: 1 hour
|
|
|
|
Multiple myeloma is the second most prevalent blood cancer (10%) after non-Hodgkin lymphoma and represents approximately 1.6% of all newly diagnosed cancers. In 2012, an estimated 89,658 people were living with myeloma in the United States. An estimated 26,850 new cases (14,090 in men and 12,760 in women) were reported in 2015 in the United States (Surveillance, Epidemiology, and End Results data). Using statistical models for analysis, rates for new myeloma cases have been rising, on average, 0.7% each year from 2010–2012. Death rates have been falling an average of 0.9% each year from 2003–2012. However, this death rate still remains significant as the vast majority of patients with myeloma will ultimately become refractory to standard treatment and lose their battle with the disease.
Large-scale genomic studies of multiple myeloma have shown that almost one-half of relapsed patients have genetic alterations that could be targeted by anticancer agents currently in clinical development. As cancer medicine continues to evolve into a more molecularly based discipline with many new treatments being developed that are aimed at specific cancer-related pathways and genetic alterations, new clinical trial designs and approaches are needed to evaluate the promise of these potential therapies.
|
|
|
|
This activity has been designed to meet the educational needs of hematologists and oncologists involved in the care of patients with multiple myeloma. |
|
|
|
After completing this activity, the participant should be better able to:
- Outline the clinical advancements in the treatment of patients with newly diagnosed myeloma
- Utilize novel targeted therapies for treating patients with relapsed/refractory myeloma
- Identify patients who are and are not eligible for stem cell transplantation
- Employ best practices for dose modification and treatment
- Identify relapsed/refractory patients for referral into clinical trials
|
|
|
|
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, the Multiple Myeloma Research Foundation, and Cancereducation.com. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
|
|
|
|
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
|
|
|
- Shaji Kumar, MD
Mayo Clinic
Rochester, MN
- C. Ola Landgren, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY
|
|
|
|
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.
Name of Faculty or Presenter |
Reported Financial Relationship |
 | |
Shaji Kumar, MD |
Consulting Fees: Celgene, Millennium, Onyx, Abvie, Sanofi, Janssen, Noxxon, Skyline
Contracted Research: Celgene, Millennium, Onyx, Abvie, Sanofi, Jannssen
|
| |
C. Ola Landgren, MD, PhD |
Consulting Fees: Celgene, Bristol-Myers Squibb, Amgen, Onyx Pharmaceuticals, Janssen
Contracted Research: Onyx Pharmaceuticals, Multiple Myeloma Research Foundation, International Myeloma Workshop
|
| |
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.
Name of Planner or Manager |
Reported Financial Relationship |
| |
Blake A. Morrison, PharmD (MMRF) |
Salary: Previously employed by Karyopharm Therapeutics
Ownership Interest (stocks, stock options or other ownership interest excluding mutual funds): Onyx Pharmaceuticals, Karyopharm Therapeutics
|
| |
Rich Parrish (Cancereducation.com) |
No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
|
| |
Michelle DiMichele (Cancereducation.com)
|
No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
|
| |
Judi Smelker-Mitchek, RN, BSN (PIM) |
No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
|
| |
Trace Hutchison, PharmD (PIM) |
No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
|
| |
Samantha Mattiucci, PharmD, CHCP (PIM) |
No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
|
| |
Jan Schultz, BSN, MSN, RN, CHCP (PIM) |
No financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
|
| |
|
|
|
|
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
|
|
|
|
There are no fees for participating and receiving CME credit for this activity. During the period December 8, 2015 through December 31, 2016, participants must read the learning objectives and faculty disclosures and study the educational activity.
PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-Test/Evaluation by Course” and search by course ID 11311. Upon registering and successfully completing the post-test with a score of 75% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
|
|
|
|
Web
|
|
|
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
|
|
|
This webcast makes use of the following requirements for proper viewing:
- A broadband Internet connection with at least DSL or LAN speed
- Windows (XP, Vista, or 7) or Apple Intel-based Macintosh operating system
- Internet browser equivalent to or higher than Internet Explorer v7.x, Mozilla Firefox v2.0, Apple Safari v3.0
- Adobe Flash Player version 10. Click here to download the latest Flash Player
- A monitor with minimum resolution 800 x 600 (1024 x 768 or higher recommended)
- 2.4 GHz Intel Pentium IV processor or equivalent
- 256 MB of RAM
|
|
Click to continue
|
|